NUTX · Insider Trading
Nutex Health Inc. Common Stock
Every open-market purchase and sale reported by NUTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-18 | Scott J Saunders | Director | Sell | −203 | −$43.49K |
| 2026-08-03 | Cheryl Yvonne Grenas | Director | M | +603 | — |
| 2026-08-03 | Scott J Saunders | Director | M | +603 | — |
| 2026-08-03 | Frank E Jaumot | Director | M | +603 | — |
| 2026-08-03 | Michael Lee Reed | Director | M | +603 | — |
| 2026-06-04 | Kelvin Spears | Director | J | +2,519 | — |
| 2026-05-29 | Thomas T. Vo | Chief Executive Officer | J | +75,747 | — |
| 2026-04-24 | Cheryl Yvonne Grenas | Director | A | +823 deriv. | — |
| 2026-04-24 | Michael Lee Reed | Director | A | +823 deriv. | — |
| 2026-04-24 | Frank E Jaumot | Director | A | +823 deriv. | — |
| 2026-04-24 | Scott J Saunders | Director | A | +823 deriv. | — |
| 2026-04-10 | Thomas T. Vo | Chief Executive Officer | J | +184,071 | — |
| 2026-03-24 | Wesley Shane Bamburg | Chief Operating Officer | M | +2,411 deriv. | — |
| 2026-03-23 | Frank E Jaumot | Director | Buy | +150 | +$14.03K |
| 2026-03-23 | Warren Hosseinion | President | Buy | +252 | +$23.71K |
| 2026-03-18 | Kelvin Spears | Director | Buy | +10 | +$945 |
| 2026-03-16 | Pamela W. Montgomery | Chief Legal Officer-Healthcare | Buy | +79 | +$7.02K |
| 2026-03-11 | Jon Christian Bates | Chief Financial Officer | M | +2,667 | — |
| 2026-03-11 | Warren Hosseinion | President | MIXED | +3,019 | −$282.29K |
| 2026-03-11 | Thomas T. Vo | Chief Executive Officer | MIXED | +5,317 | −$260.13K |
| 2026-03-11 | Kelvin Spears | Director | MIXED | +101 | −$7.07K |
| 2026-03-11 | Michael L. Chang | Chief Medical Officer | MIXED | +1,315 | −$66.31K |
| 2026-03-11 | Pamela W. Montgomery | Chief Legal Officer-Healthcare | MIXED | +1,308 | −$66.91K |
| 2026-03-11 | Elisa V Luqman | Chief Legal Officer - SEC | MIXED | +1,300 | −$67.60K |
| 2026-02-09 | Frank E Jaumot | Director | A | +603 deriv. | — |
| 2026-02-09 | Michael Lee Reed | Director | A | +603 deriv. | — |
| 2026-02-09 | Cheryl Yvonne Grenas | Director | A | +603 deriv. | — |
| 2026-02-09 | Scott J Saunders | Director | A | +603 deriv. | — |
| 2025-11-28 | Jon Christian Bates | Chief Financial Officer | Buy | +750 | +$102.53K |
| 2025-04-14 | Warren Hosseinion | President | MIXED | +2,704 | −$77.29K |
| 2025-04-14 | Joshua DeTillio | Chief Operating Officer | MIXED | +1,673 | −$32.59K |
| 2025-04-14 | Jon Christian Bates | Chief Financial Officer | MIXED | +2,611 | +$81.81K |
| 2025-04-14 | Kelvin Spears | Director | MIXED | +109 | −$2.45K |
| 2025-04-14 | Elisa V Luqman | Chief Legal Officer - SEC | MIXED | +984 | −$19.18K |
| 2025-04-14 | Pamela W. Montgomery | Chief Legal Officer-Healthcare | MIXED | +1,071 | −$20.91K |
| 2025-04-14 | Thomas T. Vo | Chief Executive Officer | MIXED | +5,895 | +$64.53K |
| 2025-04-14 | Michael L. Chang | Chief Medical Officer | MIXED | +984 | −$19.18K |
| 2025-01-10 | Thomas T. Vo | Chief Executive Officer | G | +5,000 | — |
| 2024-08-26 | Jon Christian Bates | Chief Financial Officer | Buy | +1,350 | +$28.97K |
| 2024-08-21 | Joshua DeTillio | Chief Operating Officer | Buy | +1,875 | +$33.21K |
| 2024-07-15 | Thomas T. Vo | Chief Executive Officer | A | +22,709 | — |
| 2024-06-28 | Elisa V Luqman | Chief Legal Officer-SEC | A | +37,500 deriv. | — |
| 2024-06-28 | Thomas T. Vo | Chief Executive Officer | A | +150,000 deriv. | — |
| 2024-06-28 | Warren Hosseinion | President | A | +113,265 deriv. | — |
| 2024-06-28 | Pamela W. Montgomery | Chief Legal Officer-Healthcare | A | +37,500 deriv. | — |
| 2024-06-28 | Warren Hosseinion | President | A | +113,265 deriv. | — |
| 2024-06-28 | Joshua DeTillio | Chief Operating Officer | A | +63,750 deriv. | — |
| 2024-06-28 | Michael L. Chang | Chief Medical Officer | A | +37,500 deriv. | — |
| 2024-06-28 | Jon Christian Bates | Chief Financial Officer | A | +45,000 deriv. | — |
| 2024-06-13 | Joshua DeTillio | Chief Operating Officer | Buy | +20,000 | +$10.80K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Thomas T. Vo | Chief Executive Officer | 2,281,060 | $442.89M |
| Michael L. Chang | Chief Medical Officer | 82,356 | $15.99M |
| Kelvin Spears | Director | 34,656 | $6.73M |
| Jon Christian Bates | Chief Financial Officer | 8,305 | $1.61M |
| Warren Hosseinion | President | 7,765 | $1.51M |
| Joshua DeTillio | Chief Operating Officer | 6,933 | $1.35M |
| Elisa V Luqman | Chief Legal Officer - SEC | 3,706 | $719.56K |
| Pamela W. Montgomery | Chief Legal Officer-Healthcare | 2,758 | $535.49K |
| Frank E Jaumot | Director | 753 | $146.20K |
| Cheryl Yvonne Grenas | Director | 737 | $143.10K |
| Michael Lee Reed | Director | 670 | $130.09K |
| Scott J Saunders | Director | 400 | $77.66K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NUTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.